Sartorius Stedim Biotech (FR:DIM)
:DIM
DIM Stock Chart & Stats
€166.80
€3.85(1.94%)
At close: 4:00 PM EST
€166.80
€3.85(1.94%)
Day’s Range― - ―
52-Week Range€148.75 - €224.00
Previous CloseN/A
Volume6.35K
Average Volume (3M)78.09K
Market Cap
€16.23B
Enterprise Value€18.55B
Total Cash (Recent Filing)€426.10M
Total Debt (Recent Filing)€2.75B
Price to Earnings (P/E)76.9
Beta1.29
Next Earnings
Apr 23, 2026EPS Estimate
1.23Next Dividend Ex-DateN/A
Dividend Yield0.31%
Share Statistics
EPS (TTM)1.12
Shares Outstanding97,330,410
10 Day Avg. Volume78,938
30 Day Avg. Volume78,094
Financial Highlights & Ratios
PEG Ratio1.51
Price to Book (P/B)5.00
Price to Sales (P/S)6.89
P/FCF Ratio140.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€237.43Price Target Upside42.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)5.12
Revenue Forecast (FY)€3.18B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables & ServicesSartorius Stedim Biotech’s business model relies on repeatable consumables and installed-base services, creating predictable, recurring revenue and higher customer retention. This aftermarket mix supports steady demand and revenue visibility across manufacturing cycles, strengthening durable cash flow potential.
Sharp TTM Revenue ReboundA large TTM revenue recovery with improved margins signals renewed end-market demand and better utilization of capacity. If sustained, this recovery can restore operational leverage, enable reinvestment in product development or capacity, and support medium-term revenue momentum tied to bioprocessing demand.
Improving Leverage RatioA materially lower debt-to-equity ratio reduces solvency risk and interest coverage pressure versus 2023. Improved capital structure enhances financial flexibility for strategic investment, M&A or R&D funding and lessens refinancing stress, supporting more durable balance-sheet resilience.
Bears Say
Weak Free Cash Flow ConversionSignificant FCF decline and low cash conversion versus net income weaken the company’s ability to self-fund capex, repay debt, or increase shareholder distributions. Persistent weak conversion pressures financial flexibility and makes the firm more reliant on external financing for growth or working capital needs.
Sustained Margin ShortfallCurrent net margins (~8.9% TTM) materially trail historical peaks, indicating structural margin pressure or mix shifts. If margins do not re-expand, profitability and returns will remain constrained, limiting reinvestment capacity and long-term earnings power despite top-line gains.
High Absolute Debt And Muted ROEEven with an improved leverage ratio, substantial absolute debt and a low ROE limit strategic flexibility and increase vulnerability to higher interest costs. Elevated debt levels can constrain capital allocation choices and weigh on long-term shareholder returns if earnings growth and cash conversion don’t improve.
Sartorius Stedim Biotech News
DIM FAQ
What was Sartorius Stedim Biotech’s price range in the past 12 months?
Sartorius Stedim Biotech lowest stock price was €148.75 and its highest was €224.00 in the past 12 months.
What is Sartorius Stedim Biotech’s market cap?
Sartorius Stedim Biotech’s market cap is €16.23B.
When is Sartorius Stedim Biotech’s upcoming earnings report date?
Sartorius Stedim Biotech’s upcoming earnings report date is Apr 23, 2026 which is in 28 days.
How were Sartorius Stedim Biotech’s earnings last quarter?
Sartorius Stedim Biotech released its earnings results on Feb 03, 2026. The company reported €1.12 earnings per share for the quarter, missing the consensus estimate of €1.264 by -€0.144.
Is Sartorius Stedim Biotech overvalued?
According to Wall Street analysts Sartorius Stedim Biotech’s price is currently Undervalued.
Does Sartorius Stedim Biotech pay dividends?
Sartorius Stedim Biotech pays a Notavailable dividend of €0.69 which represents an annual dividend yield of 0.31%. See more information on Sartorius Stedim Biotech dividends here
What is Sartorius Stedim Biotech’s EPS estimate?
Sartorius Stedim Biotech’s EPS estimate is 1.23.
How many shares outstanding does Sartorius Stedim Biotech have?
Sartorius Stedim Biotech has 97,330,410 shares outstanding.
What happened to Sartorius Stedim Biotech’s price movement after its last earnings report?
Sartorius Stedim Biotech reported an EPS of €1.12 in its last earnings report, missing expectations of €1.264. Following the earnings report the stock price went up 2.537%.
Which hedge fund is a major shareholder of Sartorius Stedim Biotech?
Currently, no hedge funds are holding shares in FR:DIM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sartorius Stedim Biotech
Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, filtration, purification, and fluid management services; single-use and reusable hollow-fiber membrane devices, as well as presterilized assemblies for cell and gene therapy applications; and cell harvesting and various other solutions for intensified bioprocesses. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production. It serves manufacturers of pharmaceuticals, foods, and chemicals, as well as research and development laboratories. The company was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.
DIM Stock 12 Month Forecast
Average Price Target
€237.43
▲(42.34% Upside)
Technical Analysis
Options Prices
Currently, No data available
---